Prostate Cancer International is
for 2011 by Great NonProfits
Between 1981 and 1983 researchers collected and stored blood samples from 4,500 men in Copenhagen, Denmark, as part of the Copenhagen City Heart Study. These blood samples had been carefully stored — and otherwise unused — for nearly 30 years. In 2010, a new research team decided to measure the PSA levels in these blood [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, long-term, mortality, PSA, risk, screening | 5 Comments »
There is an interesting article on Kaiser Health News today discussing the risks associated with “over-testing” of elderly and sometimes very infirm people who are at relatively low risk for specific chronic diseases, including prostate cancer.
Filed under: Diagnosis, Risk | Tagged: aging, life expectancy, mortality, over-testing, risk, screening | 7 Comments »
The association of depression with a diagnosis of and subsequent treatment for prostate cancer is well appreciated, but the prevalence of that depression and the burden it places on men with prostate cancer over time has been less well documented.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: depression, mortality, outcome, risk | 5 Comments »
As we have noted several times before, databases in selected European nations (most particularly the Scandinavian countries) allow for the possibility of highly accurate analyses of information on the diagnosis, management, and outcomes of prostate cancer (and other disorders) over time based on data from very large numbers of people.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Denmark, Diagnosis, mortality, outcome, survival | 3 Comments »
A new report in European Urology may offer some insights into the value of large, retrospective data analyses as compared to multi-center, randomized clinical trials when it comes to the assessment of the effects of different first-line treatments on the management of clinically localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: age, mortality, observation, radical prostatectomy, watchful waiting | 5 Comments »
The addition of androgen deprivation therapy (ADT) to radiation therapy for men with localized prostate cancer is common. It may be used to reduce the size of the prostate prior to brachytherapy or for longer periods in men with higher risk disease to extend survival (which has been demonstrated in large-scale, randomized, multi-center clinical trials).
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen deprivation therapy, brachytherapy, cardiovascular disease, history, mortality, radiation, risk | 4 Comments »
As we first reported in March 2010, when data were originally presented at the Genitourinary Cancers Symposium, RTOG 94-08 has shown that 4 months of androgen deprivation therapy (ADT) before and during external beam radiation therapy (EBRT) reduces the overall and the prostate cancer-specific mortality rates for men with localized prostate cancer (clinical stages T1b, [...]
Filed under: Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation, EBRT, mortality, neoadjuvant, outcome, radiation therapy, RTOG 94-08 | Leave a Comment »
A new retrospective analysis of data from > 2,300 patients suggests that African-American men are a greater risk for biochemical disease recurrence after brachytherapy alone than Hispanics or Caucasian men, but
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: African American, brachytherapy, mortality, outcome, race, recurrence | 1 Comment »
Back in 2006 a report from a research team in the Tyrol, Austria, suggested that the availability of free PSA testing for prostate cancer risk had lowered the risk of prostate cancer mortality in the Tyrol as compared to all other areas of Austria. This original study is discussed elsewhere on this web site.
Filed under: Diagnosis, Management, Risk | Tagged: mortality, PSA, screening, testing, Tyrol | 5 Comments »
A fascinating new paper based on data from the Prostate Cancer DataBase Sweden provides important insight into the consequences of delayed diagnosis and potential under-treatment of men who are diagnosed with locally advanced prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: delayed, Diagnosis, locally advanced, mortality, prostate cancer-specific | 14 Comments »
It has been known for years that marital status impacts the likelihood of stage at diagnosis and survival in a number of different types of cancer (prostate cancer included). However, a new study has now confirmed this in a large, US, population-based analysis of prostate cancer patients.
Filed under: Diagnosis, Management, Risk | Tagged: marital status, mortality, stage | Leave a Comment »
An article in Progrès en urologie states that the prostate cancer-specific mortality rate in France has been dropping by 2.5 percent per year.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: France, mortality, prostate cancer-specific | 1 Comment »
New data from the Health Professionals Follow-Up Study (HPFUS) suggest that men who are smokers at the time of diagnosis of prostate cancer are at increased risk for prostate cancer progression or recurrence and prostate cancer-specific mortality compared to those who have never smoked or who stopped at least 10 years earlier.
Filed under: Diagnosis, Living with Prostate Cancer, Risk, Uncategorized | Tagged: mortality, recurrence, risk, smoking | 1 Comment »
The annual cancer statistics report from the American Cancer Society (Cancer Facts & Figures 2011) has just been released. The report is projecting 240,890 new cases of prostate cancer diagnosis and 33,720 prostate cancer-specific deaths in 2011. These numbers are up, yet again, from the projections for 2010.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: 2011, estimates, incidence, mortality | 4 Comments »
As a follow-up to our earlier post on this topic, we have now identified the original media release issued by Kings College London and the UK’s National National Cancer Intelligence Network (NCIN) on which today’s article in The Daily Telegraph (and other media) was based. That article clearly stated that up to 49 percent of [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: mortality, prostate cancer-specific, UK, United Kingdom | 11 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site